Medical Research & News

Through a collaborative approach to research support, the Foundation is focused on improving diagnosis, treatment therapies, better understanding of the disease burden, and advocating for increased research funding that can benefit patients --- with an ultimate goal of helping researchers find a cure for cutaneous lymphoma.

American Society of Hematology Announces 2020 Scholar Award Recipients
December 2019 - The American Society of Hematology (ASH) announced the 39 recipients of its 2020 Scholar Awards. One of ASH’s most prestigious research award programs, the ASH Scholar Awards financially support fellows to junior faculty dedicated to careers in hematology research as they transition from training programs to careers as independent investigators. Awardees included cutaneous lymphoma researcher, Anjali Mishra, PhD. 
Research

Clinical Trials...Developing Innovative Drug Candidates to Improve the Lives Of Cancer Patients
Two clinical assets of Trillium Therapeutics Inc., TTI-621 and TTI-622, are designed to activate the patient’s innate and adaptive immune response. TTI-621 is an investigational agent being developed by Trillium for the treatment of cutaneous T-cell lymphoma and other cancer types.
Research

Resiquimod Study for Treating Cutaneous T-cell Lymphoma
Early studies show Resiquimod gel as a promising treatment for early stage cutaneous lymphoma. Learn more about this investigator-initiated study.
Research

FDA Approves Mogamulizumab for CTCL
The FDA has approved mogamulizumab-kpkc (Poteligeo) for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received at least 1 prior systemic therapy.
Research

Industry Spotlight: Adaptive Biotechnologies
Susan Thornton, CEO, interviewed Adaptive Biotechnologies, creators of an innovative diagnostic tool that can be used in cutaneous lymphoma.
Research

Research in Cutaneous Lymphoma: A Broad View
Since the development of the “scientific method,” people have been engaged in research in efforts to answer questions, solve problems, and add to our overall knowledge. Nowhere is this more evident than in the medical field, and in the study of cutaneous lymphoma.
Research

FLASH Study: Clinical Trial Update
Dr. Ellen Kim shares information about the role of clinical trials and specifically the FLASH [Fluorescent Light Activated Synthetic Hypericin] Study.
Research

Protein Can Help Identify Which Rashes Are Early Mycosis Fungoides
Chronic rash in a sun-protected area that doesn’t respond to topical treatment likely needs to be evaluated for mycosis fungoides, the most common variant of cutaneous T-cell lymphoma. Now, a new VA study reports that a protein expression can help make the diagnosis.
Research

Skin-Directed Tactics Optimal for Early Cutaneous Lymphoma
For patients with early-stage cutaneous lymphoma, skin-directed treatments, such as topical steroids and phototherapy, can slow or halt progression, but patients are also being treated with systemic therapies, according to the first-of-its kind research on this rare malignancy.
Answers from the Experts

FUTURE DIRECTIONS IN T-CELL CUTANEOUS LYMPHOMA
Advances are being made in improving diagnostic tools. Dr. Christiane Quelfeld presents what has become available and what the future holds.
Research

WHAT ARE FOCUS AREAS IN CUTANEOUS LYMPHOMA RESEARCH?
New breakthroughs in research offer hope of better treatments and may offer insight into the causes of cutaneous lymphoma.
Research

Modernizing Immunotherapy for Cutaneous T-cell Lymphoma
For decades, immunotherapy has been a cornerstone of systemic therapy for cutaneous T cell lymphoma (CTCL). It is therefore not surprising that modern immune-therapies, which target anti-tumor immunity in more sophisticated ways, have the potential to greatly improve our treatments for CTCL. 
Research

Epigenetics & Biology of Cutaneous T-cell Lymphomas
These are exciting times in cutaneous T-cell lymphoma (CTCL) research. The hard work of laboratory and clinical investigators worldwide is starting to bear fruit, and a number of basic discoveries in the genetic and epigenetic foundations of CTCL are now being translated into novel therapies, with great impact for patients.
Research

Medical Meeting Highlights: 3rd World Congress, T-Cell Lymphoma Forum and USCLC Annual Workshop
In a world that has 7,000 known rare diseases, with only 5% having any treatment available, the future of discovery and new treatment development in cutaneous lymphoma is promising. There is much hope for a brighter future for everyone living with this condition.